Clinical trial Recruiting at 1 site Observational Ages 18 to 100

Hepatic Lipid Metabolism in Alcohol Use Disorder

Official title: Mechanisms in Hepatic Lipid Metabolism in Alcohol Use Disorder: From Genomics, Transcriptomics to Metabolomics

Run by National Institutes of Health Clinical Center (CC) · NCT07191561 · Data updated 2026-11-12

This study tests how alcohol use disorder affects liver lipid metabolism by comparing liver biopsy transcriptomes during early and later withdrawal in adults undergoing inpatient detoxification.

Quick facts

Study typeObservational
Ages18 Years to 100 Years
SexAll
Enrollment25 (estimated)
SponsorNational Institutes of Health Clinical Center (CC)
NIH
Locations1 site (Bethesda, Maryland)
StatusRecruiting
StartedOctober 5, 2026
Main results expectedNovember 30, 2027
Study endsNovember 30, 2029
Registry record updatedOctober 8, 2026
Trial IDNCT07191561 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with alcohol use disorder entering inpatient detoxification and with liver stiffness/capacitance measurements suggesting steatosis.

Probably not a fit

Individuals who do not have hepatic steatosis or who do not undergo the planned second biopsy may not experience benefits from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will perform liver biopsies at the start of inpatient detoxification and again four weeks later when steatosis has resolved. Researchers will analyze hepatic transcriptomes to understand changes in lipid metabolism related to alcohol use and cessation. The aim is to map how gene expression in the liver shifts during detoxification and how these changes relate to lipid pathways and metabolomics. Stool microbiome data are also collected to explore connections with host metabolism. The study is centered at the NIH Clinical Center and involves adults with alcohol use disorder and hepatic steatosis.

Why it matters

Potential benefit: If successful, findings could illuminate the molecular processes linking alcohol cessation to liver lipid metabolism and guide future biomarker or therapeutic strategies.

How similar studies have gone: Previous work has shown transcriptomic changes associated with alcohol cessation, but this study contributes longitudinal liver tissue data and multi-omics integration in an inpatient setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Any individual \>=18 years of age who is enrolled in 14-AA-0181 and is seeking inpatient treatment.
* Vibration Controlled Elastography parameters with initial CAP of \>295dB/m.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

* Pregnancy
* Existing diagnosis of hyperlipidemia or essential hypertension
* Hemoglobin A1c \>= 6.5%
* Waist to hip ratio: \>=0.90 in males, \>=0.85 in females
* Existing use of cholesterol lowering medications including statins, fibrates, or other similar medications used for the purposes of treating hyperlipidemia.
* Those with evidence of severe alcoholic hepatitis with a Maddrey s Discriminant Function \> 32
* Those with other chronic liver diseases including chronic hepatitis B (positive hepatitis B surface Ag on admission), hepatitis C (positive hepatitis C RNA), or autoimmune hepatitis (clinical diagnosis based on high titer of positive ANA and or anti smooth muscle Ab and a history of autoimmune disease)
* HIV infection
* Contraindication or inability to perform a liver biopsy.

  * Participants with coagulopathy (PT/PTT values that are prolonged (Bullet) 3 seconds from the upper limit of the normal, including treatment with oral and parenteral anticoagulants), thrombocytopenia (\< 70,000), abnormal bleeding time or platelet dysfunction. Antiplatelet agents taken for cardiovascular prevention will not exclude participants, unless they cannot be stopped safely for the performance of a liver biopsy.
  * Hemoglobin level \< 11 g/dL
  * Inability to provide informed consent.

Where it's running

  • National Institutes of Health Clinical Center
    Bethesda, Maryland, United States
    Recruiting

Study contacts

  • Principal investigator: Theo Heller, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Study coordinator: Sawsan Fathma, M.D.
  • Email: sawsan.fathma@nih.gov
  • Phone: (301) 451-1273

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.